Lv4
440 积分 2024-05-13 加入
Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission
2天前
已完结
Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission
2天前
已关闭
Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission
2天前
已关闭
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
3天前
已完结
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
4天前
已关闭
Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
11天前
已完结
Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma
14天前
已完结
Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma
23天前
已关闭
Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia
25天前
已完结
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
1个月前
已完结
皖公网安备34019202002308
